BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty 2021;10:132. [PMID: 34776011 DOI: 10.1186/s40249-021-00915-3] [Cited by in Crossref: 101] [Cited by in F6Publishing: 109] [Article Influence: 101.0] [Reference Citation Analysis]
Number Citing Articles
1 Ma Y, Xu S, An Q, Qin M, Li S, Lu K, Li J, Lei L, He L, Yu H, Xie J. Coronavirus disease 2019 epidemic prediction in Shanghai under the “dynamic zero-COVID policy” using time-dependent SEAIQR model. Journal of Biosafety and Biosecurity 2022;4:105-113. [DOI: 10.1016/j.jobb.2022.06.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Tian X, Zhang Y, Wang W, Fang F, Zhang W, Zhu Z, Wan Y. The impacts of vaccination status and host factors during early infection on SARS-CoV-2 persistence: a retrospective single-center cohort study. International Immunopharmacology 2022. [DOI: 10.1016/j.intimp.2022.109534] [Reference Citation Analysis]
3 Valenzuela-fernández A, Cabrera-rodriguez R, Ciuffreda L, Perez-yanes S, Estevez-herrera J, González-montelongo R, Alcoba-florez J, Trujillo-gonzález R, García-martínez de Artola D, Gil-campesino H, Díez-gil O, Lorenzo-salazar JM, Flores C, Garcia-luis J. Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. Front Bioeng Biotechnol 2022;10. [DOI: 10.3389/fbioe.2022.1052436] [Reference Citation Analysis]
4 Petráš M, Máčalík R, Janovská D, Čelko AM, Dáňová J, Selinger E, Doleček J, Neradová S, Franklová M, Dlouhý P, Rosina J, Lesná IK. Risk factors affecting COVID-19 vaccine effectiveness identified from 290 cross-country observational studies until February 2022: a meta-analysis and meta-regression. BMC Med 2022;20:461. [DOI: 10.1186/s12916-022-02663-z] [Reference Citation Analysis]
5 Yu C, Fengzhao Z, Hongmei W, Zeyuan L, Yu L, Yuhang G, Rufei S, Qingzhu J, Xiaorong S, Xia W, Caiping S, Zhi X, Chunmei L. The impact of vaccination on patients with COVID-19 during the wave of Omicron in Shanghai. Front Public Health 2022;10. [DOI: 10.3389/fpubh.2022.1054313] [Reference Citation Analysis]
6 Smetanova J, Milota T, Rataj M, Hurnakova J, Zelena H, Horvath R. SARS-CoV-2-specific humoral and cellular immune responses to BNT162b2 vaccine in Fibrodysplasia ossificans progressiva patients. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1017232] [Reference Citation Analysis]
7 Martora F, Battista T, Marasca C, Genco L, Fabbrocini G, Potestio L. Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature. CCID 2022;Volume 15:2369-2382. [DOI: 10.2147/ccid.s388245] [Reference Citation Analysis]
8 Horváth JK, Ferenci T, Ferenczi A, Túri G, Röst G, Oroszi B. Real-Time Monitoring of the Effectiveness of Six COVID-19 Vaccines against Laboratory-Confirmed COVID-19 in Hungary in 2021 Using the Screening Method. Vaccines 2022;10:1824. [DOI: 10.3390/vaccines10111824] [Reference Citation Analysis]
9 Zhang J, Fan L, Xu H, Fu Y, Peng X, Zheng Y, Yu J, He J. Evolutionary Pattern Comparisons of the SARS-CoV-2 Delta Variant in Countries/Regions with High and Low Vaccine Coverage. Viruses 2022;14:2296. [DOI: 10.3390/v14102296] [Reference Citation Analysis]
10 Meggiolaro A, Sane Schepisi M, Farina S, Castagna C, Mammone A, Siddu A, Stefanelli P, Boccia S, Rezza G. Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: a systematic review and meta-analysis. Expert Rev Vaccines 2022;:1-11. [PMID: 36242513 DOI: 10.1080/14760584.2022.2130773] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Abdelmoneim SA, Sallam M, Hafez DM, Elrewany E, Mousli HM, Hammad EM, Elkhadry SW, Adam MF, Ghobashy AA, Naguib M, Nour El-deen AE, Aji N, Ghazy RM. COVID-19 Vaccine Booster Dose Acceptance: Systematic Review and Meta-Analysis. TropicalMed 2022;7:298. [DOI: 10.3390/tropicalmed7100298] [Reference Citation Analysis]
12 Akbar MIA, Irwinda R, Dewantiningrum J, Bernolian N, Sitepu M, Chalid MT, Noryanto M, Yeni CM, Wantania J, Budayasa AAGR, Aziz MA. Clinical Factors Associated with Maternal Death in Pregnant Women Infected by COVID-19 in Indonesia: A Multicenter Prospective Study.. [DOI: 10.21203/rs.3.rs-2007956/v1] [Reference Citation Analysis]
13 Galanis P, Vraka I, Katsiroumpa A, Siskou O, Konstantakopoulou O, Katsoulas T, Mariolis-sapsakos T, Kaitelidou D. COVID-19 Vaccine Uptake among Healthcare Workers: A Systematic Review and Meta-Analysis. Vaccines 2022;10:1637. [DOI: 10.3390/vaccines10101637] [Reference Citation Analysis]
14 Sun C, Chi H, Yuan F, Li J, Yang J, Zheng A, Wang F, Sun L, Zhang Y, Hu P, Jiao L, Deng Y, Xie L. An antibody cocktail with broadened mutational resistance and effective protection against SARS-CoV-2. Sci China Life Sci 2022;:1-15. [PMID: 36184693 DOI: 10.1007/s11427-022-2166-y] [Reference Citation Analysis]
15 Bhuiyan TR, Al Banna H, Kaisar MH, Karmakar PC, Hakim A, Akter A, Ahmed T, Tauheed I, Islam S, Hasnat MA, Sumon MA, Rashed A, Ghosh S, Clemens JD, Banu S, Shirin T, Weiskopf D, Sette A, Chowdhury F, Qadri F. Correlation of antigen-specific immune response with disease severity among COVID-19 patients in Bangladesh. Front Immunol 2022;13:929849. [DOI: 10.3389/fimmu.2022.929849] [Reference Citation Analysis]
16 Smetanova J, Milota T, Rataj M, Hurnakova J, Zelena H, Sediva A, Horvath R. Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs. Front Immunol 2022;13:1010808. [DOI: 10.3389/fimmu.2022.1010808] [Reference Citation Analysis]
17 Kpokiri EE, Mcdonald K, Gebreyohannes JA, Osorio L, Nath TC, Talavera-urdanivia VA, Akinwale PO, Manabe YC, Castelnuovu B, Tang W, Yilma D, Mihut M, Ezechi O, Iwelunmor J, Kaba M, Abdissa A, Tucker JD. Research Mentorship in Low and Middle-Income Countries: A Global Qualitative Evidence Synthesis of Data from a Crowdsourcing Open Call and Scoping Review.. [DOI: 10.1101/2022.09.19.22280121] [Reference Citation Analysis]
18 Rana R, Kant R, Huirem RS, Bohra D, Ganguly NK. Omicron variant: Current insights and future directions. Microbiol Res 2022;265:127204. [PMID: 36152612 DOI: 10.1016/j.micres.2022.127204] [Reference Citation Analysis]
19 Salamanca-Neita LH, Carvajal Ó, Carvajal JP, Forero-Castro M, Segura NA. Comparison of Four Real-Time Polymerase Chain Reaction Assays for the Detection of SARS-CoV-2 in Respiratory Samples from Tunja, Boyacá, Colombia. Trop Med Infect Dis 2022;7:240. [PMID: 36136651 DOI: 10.3390/tropicalmed7090240] [Reference Citation Analysis]
20 Shao W, Chen X, Zheng C, Liu H, Wang G, Zhang B, Li Z, Zhang W. Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Variants of Concern in Real-world: a Literature Review and Meta-analysis. Emerg Microbes Infect 2022;:1-75. [PMID: 36069511 DOI: 10.1080/22221751.2022.2122582] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Wagner MJ, Hennessy C, Beeghly A, French B, Shah DP, Croessmann S, Vilar-Compte D, Ruiz-Garcia E, Ingham M, Schwartz GK, Painter CA, Chugh R, Fecher L, Park C, Zamulko O, Trent JC, Subbiah V, Khaki AR, Tachiki L, Nakasone ES, Loggers ET, Labaki C, Saliby RM, McKay RR, Ajmera A, Griffiths EA, Puzanov I, Tap WD, Hwang C, Tejwani S, Jhawar SR, Hayes-Lattin B, Wulff-Burchfield E, Kasi A, Reuben DY, Nagaraj G, Joshi M, Polimera H, Kulkarni AA, Esfahani K, Kwon DH, Paoluzzi L, Bilen MA, Durbin EB, Grivas P, Warner JL, Davis EJ; COVID-19 and Cancer Consortium. Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study. Cancers (Basel) 2022;14:4334. [PMID: 36077869 DOI: 10.3390/cancers14174334] [Reference Citation Analysis]
22 González S, Olszevicki S, Gaiano A, Baino ANV, Regairaz L, Salazar M, Pesci S, Marín L, Martínez VVG, Varela T, Ceriani L, Garcia E, Kreplak N, Navarro A, Estenssoro E, Marsico F. Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study. Lancet Reg Health Am 2022;13:100316. [PMID: 35872665 DOI: 10.1016/j.lana.2022.100316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Jin Q, Li W, Yu W, Zeng M, Liu J, Xu P. Analysis and identification of potential type II helper T cell (Th2)-Related key genes and therapeutic agents for COVID-19. Computers in Biology and Medicine 2022. [DOI: 10.1016/j.compbiomed.2022.106134] [Reference Citation Analysis]
24 Akbulut S, Gokce A, Boz G, Saritas H, Unsal S, Ozer A, Akbulut MS, Colak C. Evaluation of Vaccine Hesitancy and Anxiety Levels among Hospital Cleaning Staff and Caregivers during COVID-19 Pandemic. Vaccines 2022;10:1426. [DOI: 10.3390/vaccines10091426] [Reference Citation Analysis]
25 Pandey R, Mesharm A. Mortality analysis in cases of COVID-19 during the second wave at a tertiary care center in western India. IJPP 2022;9:180-186. [DOI: 10.18231/j.ijpp.2022.032] [Reference Citation Analysis]
26 de Jesus MAS, Hojo-Souza NS, de Moraes TR, Guidoni DL, de Souza FSH. Profile of Brazilian inpatients with COVID-19 vaccine breakthrough infection and risk factors for unfavorable outcome. Rev Panam Salud Publica 2022;46:e106. [PMID: 36016834 DOI: 10.26633/RPSP.2022.106] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Tatarević T, Tkalčec I, Stranić D, Tešović G, Matijević R. Knowledge and attitudes of pregnant women on maternal immunization against COVID-19 in Croatia. J Perinat Med 2022. [PMID: 35993847 DOI: 10.1515/jpm-2022-0171] [Reference Citation Analysis]
28 Pires C. Global Predictors of COVID-19 Vaccine Hesitancy: A Systematic Review. Vaccines 2022;10:1349. [DOI: 10.3390/vaccines10081349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
29 Shui X, Wang F, Li L, Liang Q. COVID-19 vaccine acceptance among healthcare workers in China: A systematic review and meta-analysis. PLoS One 2022;17:e0273112. [PMID: 35960730 DOI: 10.1371/journal.pone.0273112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Ioannou P, Tzalis S, Pasparaki E, Spentzouri D, Konidaki M, Papakitsou I, Spernovasilis N, Papanikolaou N, Samonis G, Kofteridis DP. COVID-19 Disease and Vaccination: Knowledge, Fears, Perceptions and Feelings of Regret for Not Having Been Vaccinated among Hospitalized Greek Patients Suffering SARS-CoV-2 Infection. Infectious Disease Reports 2022;14:587-96. [DOI: 10.3390/idr14040063] [Reference Citation Analysis]
31 Anupong S, Chantanasaro T, Wilasang C, Jitsuk NC, Sararat C, Sornbundit K, Pattanasiri B, Chadsuthi S, Modchang C. Heterologous vaccination as a strategy to minimize inequity in COVID-19 vaccine access: A modeling study in Thailand.. [DOI: 10.1101/2022.08.05.22278489] [Reference Citation Analysis]
32 Agaku IT, Adeoye C, Long TG. Geographic, Occupational, and Sociodemographic Variations in Uptake of COVID-19 Booster Doses Among Fully Vaccinated US Adults, December 1, 2021, to January 10, 2022. JAMA Netw Open 2022;5:e2227680. [PMID: 35984657 DOI: 10.1001/jamanetworkopen.2022.27680] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Herman B, Wong MC, Viwattanakulvanid P. Vaccination status, favipiravir, and micronutrient supplementation roles in post-COVID symptoms: A longitudinal study. PLoS ONE 2022;17:e0271385. [DOI: 10.1371/journal.pone.0271385] [Reference Citation Analysis]
34 Fu Y, Zhao J, Wei X, Han P, Yang L, Ren T, Zhan S, Li L. Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies. Front Public Health 2022;10:917732. [DOI: 10.3389/fpubh.2022.917732] [Reference Citation Analysis]
35 Sharma P, Basu S, Mishra S, Mundeja N, Charan BS, Singh G, Singh MM. COVID-19 Vaccine Acceptance and Its Determinants in the General Population of Delhi, India: A State Level Cross-Sectional Survey. Cureus 2022. [DOI: 10.7759/cureus.26936] [Reference Citation Analysis]
36 Niyomnaitham S, Quan Toh Z, Wongprompitak P, Jansarikit L, Srisutthisamphan K, Sapsutthipas S, Jantraphakorn Y, Mingngamsup N, Licciardi PV, Chokephaibulkit K. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults. Hum Vaccin Immunother 2022;:2091865. [PMID: 35816053 DOI: 10.1080/21645515.2022.2091865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
37 Aljamaan F, Temsah M, Alhasan K, Alenezi S, Alhaboob A, Alrabiaah A, Batais M, Alshahrani F, Assiri RA, Bafaqih H, Alaraj A, Al Qadrah B, Alhaidary A, Saad K, Saddik B, Halwani R, Rabaan AA, Al-subaie S, Barry M, Al-tawfiq JA. SARS-CoV-2 variants and the global pandemic challenged by vaccine uptake during the emergence of the Delta variant: A national survey seeking vaccine hesitancy causes. Journal of Infection and Public Health 2022;15:773-80. [DOI: 10.1016/j.jiph.2022.06.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Shirzadeh M, Monhemi H, eftekhari M. Large interfacial relocation in RBD-ACE2 complex may explain fast-spreading property of Omicron. Journal of Molecular Structure 2022. [DOI: 10.1016/j.molstruc.2022.133842] [Reference Citation Analysis]
39 Sáez-Peñataro J, Torres F, Bartra J, Bascuas J, Vilella A, Tortajada M, Quesada S, González E, López-Suñé E, Castells A, Serrano S, Camacho C, Trilla A, Calvo G; VigilVacCOVID Group. Tolerability and Reactogenicity Profile of mRNA SARS-Cov-2 Vaccines from a Mass Vaccination Campaign in a Tertiary Hospital: Between-Vaccine and Between-Population Prospective Observational Study (VigilVacCOVID Study). BioDrugs 2022. [PMID: 35764768 DOI: 10.1007/s40259-022-00543-9] [Reference Citation Analysis]
40 Pálinkás A, Sándor J. Effectiveness of COVID-19 Vaccination in Preventing All-Cause Mortality among Adults during the Third Wave of the Epidemic in Hungary: Nationwide Retrospective Cohort Study. Vaccines 2022;10:1009. [DOI: 10.3390/vaccines10071009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Meggiolaro A, Schepisi MS, Farina S, Castagna C, Mammone A, Siddu A, Stefanelli P, Boccia S, Rezza G. Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalisation: a systematic review and meta-analysis.. [DOI: 10.1101/2022.06.23.22276809] [Reference Citation Analysis]
42 Murali S, Sakthivel M, Pattabi K, Venkatasamy V, Thangaraj JWV, Shete A, Varghese AJ, Arjun J, Kumar CPG, Yadav PD, Sahay R, Majumdar T, Dudhmal M, Sivalingam A, Dhanapal SR, Durai Samy A, Radhakrishnan V, Muni Krishnaiah MM, Arunachalam S, Gandhi PMK, Govindasamy E, Chinnappan P, Sekar DPV, Marappan P, Pounraj E, Ganeshkumar P, Jagadeesan M, Narnaware M, Bedi GS, Kaur P, Murhekar M. Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (CovishieldTM) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021. Vaccines (Basel) 2022;10:970. [PMID: 35746578 DOI: 10.3390/vaccines10060970] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Saberiyan M, Karimi E, Khademi Z, Movahhed P, Safi A, Mehri-Ghahfarrokhi A. SARS-CoV-2: phenotype, genotype, and characterization of different variants. Cell Mol Biol Lett 2022;27:50. [PMID: 35715738 DOI: 10.1186/s11658-022-00352-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Lazarus R, Taucher C, Brown C, Corbic I, Danon L, Dubischar K, Duncan CJA, Eder-Lingelbach S, Faust SN, Green C, Gokani K, Hochreiter R, Wright JK, Kwon D, Middleditch A, Munro APS, Naker K, Penciu F, Price D, Querton B, Riaz T, Ross-Russell A, Sanchez-Gonzalez A, Wardle H, Warren S, Finn A; Valneva Phase 1 Trial Group. Safety and immunogenicity of the inactivated whole-virus adjuvanted vaccine VLA2001: a randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults. J Infect 2022:S0163-4453(22)00361-9. [PMID: 35718205 DOI: 10.1016/j.jinf.2022.06.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
45 Yarovaya OI, Shcherbakov DN, Borisevich SS, Sokolova AS, Gureev MA, Khamitov EM, Rudometova NB, Zybkina AV, Mordvinova ED, Zaykovskaya AV, Rogachev AD, Pyankov OV, Maksyutov RA, Salakhutdinov NF. Borneol Ester Derivatives as Entry Inhibitors of a Wide Spectrum of SARS-CoV-2 Viruses. Viruses 2022;14:1295. [PMID: 35746766 DOI: 10.3390/v14061295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
46 Alzarea AI, Khan YH, Alatawi AD, Alanazi AS, Alzarea SI, Butt MH, Almalki ZS, Alahmari AK, Mallhi TH. Surveillance of Post-Vaccination Side Effects of COVID-19 Vaccines among Saudi Population: A Real-World Estimation of Safety Profile. Vaccines (Basel) 2022;10:924. [PMID: 35746532 DOI: 10.3390/vaccines10060924] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
47 Filipenko ML, Oskorbin IP, Shamovskaya DV, Kharpov EA, Stepanov AA, Romanov VV, Kuznetsov VV, Boyarskikh UA, Kechin AA, Pechkovsky EV, Krivoruchko AB, Ivanov AM, Kushlinskii NE, Vlasov VV. Development of a Test System to Detect the Omicron Variant of SARS-CoV-2 and the Frequency of Its Detection in Patients. Bull Exp Biol Med 2022;173:229-234. [DOI: 10.1007/s10517-022-05524-0] [Reference Citation Analysis]
48 Jacobsen H, Sitaras I, Jurgensmeyer M, Mulders MN, Goldblatt D, Feikin DR, Bar-Zeev N, Higdon MM, Knoll MD. Assessing the Reliability of SARS-CoV-2 Neutralization Studies That Use Post-Vaccination Sera. Vaccines (Basel) 2022;10:850. [PMID: 35746460 DOI: 10.3390/vaccines10060850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
49 Brazete C, Pinto M, Sá L, Aguiar A, Alves F, Duarte R. Evaluation of the Real-World Effectiveness of Vaccines against COVID-19 at a Local Level: Protocol for a Test-Negative Case-Control Study. Vaccines (Basel) 2022;10:822. [PMID: 35632578 DOI: 10.3390/vaccines10050822] [Reference Citation Analysis]
50 Wang D, Chukwu A, Mwanyika-sando M, Abubakari SW, Assefa N, Madzorera I, Hemler EC, Ismail A, Lankoande B, Mapendo F, Millogo O, Workneh F, Azemraw T, Febir LG, James C, Tinkasimile A, Asante KP, Baernighausen T, Berhane Y, Killewo J, Oduola AM, Sie A, Smith ER, Soura AB, Tajudeen R, Vuai S, Fawzi WW. Levels and determinants of COVID-19 vaccine hesitancy among sub-Saharan African adolescents.. [DOI: 10.1101/2022.05.18.22275274] [Reference Citation Analysis]
51 Sheikhi F, Yousefian N, Tehranipoor P, Kowsari Z. Estimation of the basic reproduction number of Alpha and Delta variants of COVID-19 pandemic in Iran. PLoS One 2022;17:e0265489. [PMID: 35580114 DOI: 10.1371/journal.pone.0265489] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Fano V, Coviello E, Consonni D, Agresta A, Orsini N, Crielesi A, Miglietta AS, Pasqua C, Vairo F, Vivaldi F, De Angelis G, Colaiocco G, Fabiani M. COVID-19 vaccines coverage and effectiveness against SARS-CoV-2 infection among residents in the largest Health Authority of Lazio region (Italy): a population-based cohort study. Expert Rev Vaccines 2022. [PMID: 35584901 DOI: 10.1080/14760584.2022.2080057] [Reference Citation Analysis]
53 Foti JJ, Lema K, Strickland J, Tjon E, Li A, Rivera A, Cabral C, Cormier L, Dowal L, Rao S, Vemulapalli V, Flechtner JB. The ATLAS™ screening assay reveals distinct CD4+ and CD8+ SARS-CoV-2 antigen response profiles which have implications to Omicron cellular immunity.. [DOI: 10.1101/2022.05.17.491668] [Reference Citation Analysis]
54 Wang X, Rcheulishvili N, Cai J, Liu C, Xie F, Hu X, Yang N, Hou M, Papukashvili D, He Y, Wang PG. Development of DNA Vaccine Candidate against SARS-CoV-2. Viruses 2022;14:1049. [DOI: 10.3390/v14051049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Hara M, Furue T, Fukuoka M, Iwanaga K, Matsuishi E, Miike T, Sakamoto Y, Mukai N, Kinugasa Y, Shigyo M, Sonoda N, Tanaka M, Arase Y, Tanaka Y, Nakashima H, Irie S, Hirota Y. Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study. Vaccines 2022;10:779. [DOI: 10.3390/vaccines10050779] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Mohseni Afshar Z, Barary M, Hosseinzadeh R, Karim B, Ebrahimpour S, Nazary K, Sio TT, Sullman MJM, Carson-Chahhoud K, Moudi E, Babazadeh A. COVID-19 vaccination challenges: a mini-review. Hum Vaccin Immunother 2022;:1-9. [PMID: 35512088 DOI: 10.1080/21645515.2022.2066425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
57 Gudina EK, Ali S, Froeschl G. Omicron: A Blessing in Disguise? Front Public Health 2022;10:875022. [DOI: 10.3389/fpubh.2022.875022] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Sendi P, Tande AJ. Analyzing COVID-19 vaccine efficacy in vulnerable communities: efforts Beyond Addressing vaccine inequity. Clinical Microbiology and Infection 2022. [DOI: 10.1016/j.cmi.2022.04.012] [Reference Citation Analysis]
59 Kouhpayeh H, Ansari H. Adverse Events Following COVID-19 Vaccination: A Systematic Review and Meta-analysis. International Immunopharmacology 2022. [DOI: 10.1016/j.intimp.2022.108906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Ahmed Syed M, Sameer Al Nuaimi A, Abdulla A/qotba H. Risk of SARS-CoV2 by vaccination status and population characteristics in Qatar. Clinical Infection in Practice 2022. [DOI: 10.1016/j.clinpr.2022.100148] [Reference Citation Analysis]
61 Nakhaeizadeh M, Chegeni M, Adhami M, Sharifi H, Gohari MA, Iranpour A, Azizian M, Mashinchi M, Baneshi MR, Karamouzian M, Haghdoost AA, Jahani Y, Gosak M. Estimating the Number of COVID-19 Cases and Impact of New COVID-19 Variants and Vaccination on the Population in Kerman, Iran: A Mathematical Modeling Study. Computational and Mathematical Methods in Medicine 2022;2022:1-11. [DOI: 10.1155/2022/6624471] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Liu S, Kang M, Zhao N, Zhuang Y, Li S, Song T. Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities. Medical Review 2022;2:169-196. [DOI: 10.1515/mr-2021-0021] [Reference Citation Analysis]
63 Acuti Martellucci C, Flacco ME, Soldato G, Di Martino G, Carota R, Caponetti A, Manzoli L. Effectiveness of COVID-19 Vaccines in the General Population of an Italian Region before and during the Omicron Wave. Vaccines 2022;10:662. [DOI: 10.3390/vaccines10050662] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
64 Golec M, Fronczek M, Zembala-john J, Chrapiec M, Konka A, Wystyrk K, Botor H, Brzoza Z, Kasperczyk S, Bułdak RJ. Early and Longitudinal Humoral Response to the SARS-CoV-2 mRNA BNT162b2 Vaccine in Healthcare Workers: Significance of BMI, Adipose Tissue and Muscle Mass on Long-Lasting Post-Vaccinal Immunity. Viruses 2022;14:868. [DOI: 10.3390/v14050868] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
65 González S, Olszevicki S, Gaiano A, Varela Baino AN, Regairaz L, Salazar M, Pesci S, Marín L, González Martínez VV, Varela T, Ceriani L, Garcia E, Kreplak N, Navarro A, Estenssoro E, Marsico F. Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina.. [DOI: 10.1101/2022.04.18.22273978] [Reference Citation Analysis]
66 Tian X, Zhang Y, Wang W, Fang F, Zhang W, Wan Y, Zhu Z. Comprehensive analyses reveal the impacts of vaccination status and physiological variables in early infection on viral persistence in COVID-19 patients: a retrospective single-center cohort study.. [DOI: 10.1101/2022.04.14.22273860] [Reference Citation Analysis]
67 Bhattacharyya A, Singh S, Sakshi S, Seth A, Rai SN. Association of Vaccine Hesitancy with Demographics, and Mental Health – United States Household Pulse Survey Study.. [DOI: 10.1101/2022.04.13.22273843] [Reference Citation Analysis]
68 Murali S, Sakthivel M, P K, Venkataswamy V, Thangaraj JWV, Shete A, John A, Arjun J, C P GK, Yadav PD, Sahay R, Majumdar T, Dhudhmal M, Sivalingam A, D SR, D A, R V, M MM, A S, M P, G E, C P, S DPV, M P, P E, Parasuraman G, M J, Narnaware MS, Bedi GS, Kaur P, Murhekar MV. Effectiveness of ChAdOx1 nCoV-19 Corona Virus Vaccine (Covishield™) in preventing SARS-CoV2 infection, Chennai, Tamil Nadu, India, 2021.. [DOI: 10.1101/2022.04.15.22273859] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Nasreen S, Febriani Y, Velásquez García HA, Zhang G, Tadrous M, Buchan SA, Righolt CH, Mahmud SM, Janjua NZ, Krajden M, De Serres G, Kwong JC. Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study.. [DOI: 10.1101/2022.04.13.22273825] [Reference Citation Analysis]
70 Chen L, Cai X, Zhao T, Han B, Xie M, Cui J, Zhang J, Wang C, Liu B, Lu Q, Cui F. Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis. Vaccines 2022;10:596. [DOI: 10.3390/vaccines10040596] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
71 Mohraz M, Salehi M, Tabarsi P, Abbasi-Kangevari M, Ghamari SH, Ghasemi E, Amini Pouya M, Rezaei N, Ahmadi N, Heidari K, Malekpour MR, Nasiri M, Amirzargar AA, Saeedi Moghaddam S, Larijani B, Hosseini H. Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults. BMJ Open 2022;12:e056872. [PMID: 35396297 DOI: 10.1136/bmjopen-2021-056872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
72 Qin C, Wang R, Tao L, Liu M, Liu J. Association Between Risk Perception and Acceptance for a Booster Dose of COVID-19 Vaccine to Children Among Child Caregivers in China. Front Public Health 2022;10:834572. [PMID: 35372197 DOI: 10.3389/fpubh.2022.834572] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
73 Chavda VP, Bezbaruah R, Athalye M, Parikh PK, Chhipa AS, Patel S, Apostolopoulos V. Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena. Viruses 2022;14:759. [DOI: 10.3390/v14040759] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
74 Ding D, Zhang R. China's COVID-19 Control Strategy and Its Impact on the Global Pandemic. Front Public Health 2022;10:857003. [PMID: 35359767 DOI: 10.3389/fpubh.2022.857003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
75 Pludowski P, Takacs I, Boyanov M, Belaya Z, Diaconu CC, Mokhort T, Zherdova N, Rasa I, Payer J, Pilz S. Clinical Practice in the Prevention, Diagnosis and Treatment of Vitamin D Deficiency: A Central and Eastern European Expert Consensus Statement. Nutrients 2022;14:1483. [DOI: 10.3390/nu14071483] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
76 Gudina EK, Mekonnen Z, Yilma D. Vaccine Inequity and Hesitancy: A Vicious Cycle Undermining the Fight Against the COVID-19 Pandemic. RMHP 2022;Volume 15:865-9. [DOI: 10.2147/rmhp.s360480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Rodriguez-morales AJ, Franco OH. Assessing the effectiveness of COVID-19 vaccines in older people in Latin America. The Lancet Healthy Longevity 2022;3:e219-e220. [DOI: 10.1016/s2666-7568(22)00073-3] [Reference Citation Analysis]
78 Fano V, Crielesi A, Coviello E, Fabiani M, Salvatore Miglietta A, Colaiocco G, Moretti I, Pasqua C, Vivaldi F, De Angelis G, Cerimele M. Effectiveness of the Comirnaty and the Vaxzevria vaccines in preventing SARS-CoV-2 infection among residents in Lazio region (Italy). Vaccine 2022:S0264-410X(22)00208-0. [PMID: 35341646 DOI: 10.1016/j.vaccine.2022.02.063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Lippi G, Salvagno GL, Henry BM, Pighi L, De Nitto S, Gianfilippi G. Variación longitudinal comparativa de los anticuerpos totales, IgG e IgA contra el SARS-CoV-2 en receptores de la vacuna BNT162b2. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2022;3:45-50. [DOI: 10.1515/almed-2021-0095] [Reference Citation Analysis]
80 Amodio E, Vella G, Restivo V, Casuccio A, Vitale F; on behalf of the COVID-19 Surveillance Working Group of the University of Palermo. Effectiveness of mRNA COVID-19 Vaccination on SARS-CoV-2 Infection and COVID-19 in Sicily over an Eight-Month Period. Vaccines 2022;10:426. [DOI: 10.3390/vaccines10030426] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Soegiarto G, Fajar J, Wulandari L, Anshory M, Ilmawan M, Asmiragani A, Illiyana H, Adam A, Lamadi S, Sa'adah U, Yuantoko T, Nanda E, Rachmawati F, Rahmadani N, Talilah R, Katipana M, Susanto S, Hindom M, Anjasari U, Hidayah N, Fadilla N, Lekatompessy V, Phoenna U, Tamara F, Kartini D, Mahendra A, Permana A, Pasaribu E, Dhama K, Harapan H. Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials. F1000Res 2022;11:299. [DOI: 10.12688/f1000research.110281.1] [Reference Citation Analysis]
82 Gao P, Cai S, Liu Q, Du M, Liu J, Liu M. Effectiveness and Safety of SARS-CoV-2 Vaccines among Children and Adolescents: A Systematic Review and Meta-Analysis. Vaccines 2022;10:421. [DOI: 10.3390/vaccines10030421] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
83 Rajakaruna M, Rajakaruna H, Rajakaruna R. Dynamical regulations on mobility and vaccinations for controlling COVID-19 spread. Sci Rep 2022;12:3554. [PMID: 35241699 DOI: 10.1038/s41598-022-07371-5] [Reference Citation Analysis]
84 Mattiuzzi C, Lippi G. COVID-19 vaccination is highly effective to prevent SARS-CoV-2 circulation. Journal of Infection and Public Health 2022. [DOI: 10.1016/j.jiph.2022.03.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Kountouras J, Gialamprinou D, Kotronis G, Papaefthymiou A, Economidou E, Soteriades ES, Vardaka E, Chatzopoulos D, Tzitiridou-chatzopoulou M, Papazoglou DD, Doulberis M. Ofeleein i mi Vlaptin—Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic. Medicina 2022;58:309. [DOI: 10.3390/medicina58020309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Prosser A, Helfer B, Streiner DL. Estimating the risk reduction of isolation on COVID-19 non-household transmission and severe/critical illness in non-immune individuals: September to November 2021.. [DOI: 10.1101/2022.02.05.22270453] [Reference Citation Analysis]
87 Ma Y, Deng J, Liu Q, Du M, Liu M, Liu J. Effectiveness and Safety of COVID-19 Vaccine among Pregnant Women in Real-World Studies: A Systematic Review and Meta-Analysis. Vaccines 2022;10:246. [DOI: 10.3390/vaccines10020246] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
88 Khandia R, Singhal S, Alqahtani T, Kamal MA, El-Shall NA, Nainu F, Desingu PA, Dhama K. Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. Environ Res 2022;209:112816. [PMID: 35093310 DOI: 10.1016/j.envres.2022.112816] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 72.0] [Reference Citation Analysis]
89 Budiyanto A, Anggraini M, Hidayanto AN. Predictive Analytics Comparison of Achieving Herd Immunity from COVID-19 in Indonesia and India Based on Fully Vaccinated People. 2021 International Seminar on Machine Learning, Optimization, and Data Science (ISMODE) 2022. [DOI: 10.1109/ismode53584.2022.9742823] [Reference Citation Analysis]
90 Hager KJ, Marc GP, Gobeil P, Diaz RS, Heizer G, Llapur C, Makarkov AI, Vasconcellos E, Pillet S, Riera F, Bhutada K, Wolff PG, Wallace G, Aazami H, Jones CE, Polack FP, Atkins J, Boulay I, Dhaliwall J, Charland N, Couture M, Jiang-wright J, Landry N, Lapointe S, Lorin A, Mahmood A, Moulton LH, Pahmer E, Parent J, Saxena P, Séguin A, Tran L, Breuer T, Ceregido MA, Koutsoukos M, Roman F, Namba J, D’aoust M, Trepanier S, Kimura Y, Ward BJ, The CoVLP Study Team. Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03.. [DOI: 10.1101/2022.01.17.22269242] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
91 Sultan I, Tbakhi A, Abuatta O, Mubarak S, Alsmadi O, Edilbi A, Al-ani R, Makhlouf M, Hajir R, Khreisat O, Al-ruzzieh MA, Abdelrazeq H, Mansour A. Distinct Vaccine Efficacy Rates Among Health Care Workers During a COVID-19 Outbreak in Jordan.. [DOI: 10.1101/2022.01.15.22269356] [Reference Citation Analysis]
92 Meng H, Mao J, Ye Q. Booster vaccination strategy: Necessity, Immunization Objectives, Immunization Strategy and Safety. J Med Virol 2022. [PMID: 35028946 DOI: 10.1002/jmv.27590] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
93 Herman B, Viwattanakulvanid P, Dzulhadj A, Oo AC, Patricia K, Pongpanich S. EFFECT OF FULL VACCINATION AND POST-COVID OLFACTORY DYSFUNCTION IN RECOVERED COVID-19 PATIENT. A RETROSPECTIVE LONGITUDINAL STUDY WITH PROPENSITY MATCHING.. [DOI: 10.1101/2022.01.10.22269007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
94 Qin C, Wang R, Tao L, Liu M, Liu J. Acceptance of a Third Dose of COVID-19 Vaccine and Associated Factors in China Based on Health Belief Model: A National Cross-Sectional Study. Vaccines (Basel) 2022;10:89. [PMID: 35062750 DOI: 10.3390/vaccines10010089] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 23.0] [Reference Citation Analysis]
95 Gaio V, Silva A, Amaral P, Viana JF, Leite PP, Dias CM, Kislaya I, Nunes B, Machado A. COVID-19 vaccine effectiveness among healthcare workers in Portugal: results from a hospital-based cohort study, December 2020 to November 2021.. [DOI: 10.1101/2022.01.07.22268889] [Reference Citation Analysis]
96 Verma MK, Verma YK, Raghavendra Rao M. SARS, MERS, nSARS-CoV-2 infections and diseases: Emerging threats to public health. Nanotechnological Applications in Virology 2022. [DOI: 10.1016/b978-0-323-99596-2.00017-0] [Reference Citation Analysis]
97 Brewer-smyth K. COVID-19 Trauma: The New Complex Adverse Childhood Experience. Adverse Childhood Experiences 2022. [DOI: 10.1007/978-3-031-08801-8_7] [Reference Citation Analysis]
98 Mazzoni A, Vanni A, Spinicci M, Lamacchia G, Kiros ST, Rocca A, Capone M, Di Lauria N, Salvati L, Carnasciali A, Mantengoli E, Farahvachi P, Zammarchi L, Lagi F, Colao MG, Liotta F, Cosmi L, Maggi L, Bartoloni A, Rossolini GM, Annunziato F. Long-lasting cellular immunity to SARS-CoV-2 following infection or vaccination and implications for booster strategies.. [DOI: 10.1101/2021.12.29.21268469] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
99 Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Aghayari Sheikh Neshin S, Khatami A, Turner DL, Djalalinia S, Mousavi SA, Mardani-Fard HA, Kasaeian A, Turner RJ. Effectiveness of COVID-19 Vaccines against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical Studies. Vaccines (Basel) 2021;10:23. [PMID: 35062684 DOI: 10.3390/vaccines10010023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
100 Fuse-nagase Y, Nagase M. Diversity in antibody titer at an average of 87 days after the second dose of BNT162b2 mRNA coronavirus disease 2019 vaccine: data from a predominantly elderly population in a practice in Tokyo.. [DOI: 10.1101/2021.12.22.21268296] [Reference Citation Analysis]
101 Lippi G, Salvagno GL, Henry BM, Pighi L, De Nitto S, Gianfilippi G. Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2022;3:39-43. [DOI: 10.1515/almed-2021-0086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Prosser A, Helfer B, Streiner DL. Evaluating the number of unvaccinated people needed to exclude to prevent SARS-CoV-2 transmissions.. [DOI: 10.1101/2021.12.08.21267162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Tian T, Jiang Y, Zhang Y, Li Z, Wang X, Zhang H. COVINet: A deep learning-based and interpretable prediction model for the county-wise trajectories of COVID-19 in the United States.. [DOI: 10.1101/2020.05.26.20113787] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]